Key facts
- This page summarizes PATRICK DEVAL L's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2023, 16:15.
PATRICK DEVAL L - 07 Jun 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 07 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2023, 16:15:20 UTC
- Prior SEC filing
- 05 Jun 2023
- Next SEC filing
- 12 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Bodenrader, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
PATRICK DEVAL L filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 09 Jun 2023.
Change
- Previous filing in this sequence was filed on 05 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CERE
transaction
Common Stock
Award
- Transaction value
- Shares
- +3,282
- Change %
- Price
- Shares after
- 3,282
- Date
- 07 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CERE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,780
- Change %
- Price
- $0.000000
- Shares after
- 13,780
- Date
- 07 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,780
- Exercise price
- $32.60
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.
Footnote F2
100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.